These low rates of EGFR mutations in patients with ILD were replicated in a study by Honda et al., where the prevalence of EGFR, KRAS, and BRAF driver gene mutations was 1.9, 20.4%, and 3.7%, respectively [102]. This evidence concerns the gene EGFR and interstitial lung disease.